Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Dose Escalation/Expansion Study of the Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX (CAIX)-Expressing Solid Tumors

Next Previous
Search
Trial Profile

A Phase 1b Dose Escalation/Expansion Study of the Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX (CAIX)-Expressing Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lutetium-177-DOTA-girentuximab (Primary) ; Peposertib (Primary) ; Girentuximab Zr-89
  • Indications Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms STARSTRUCK
  • Sponsors Telix Pharmaceuticals

    • Most Recent Events

    • 18 Oct 2023 According to Telix Pharmaceuticals media release, the first patients have now been dosed
    • 19 Jul 2023 According to Telix Pharmaceuticals media release, study will enrol up to 80 patients with CAIX- expressing solid tumours at Australian sites.
    • 18 Jul 2023 According to Telix Pharmaceuticals Limited, first patient has been dosed in this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top